The impact of compound Danshen dropping pills on ventricular remodeling and cardiac function after acute anterior wall myocardial infarction: a multicenter, randomized, double-blind, placebo-controlled clinical trial

The First Affiliated Hospital of Nanjing Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Aged 18-75 years, gender unlimited;
•2. According to the guidelines for diagnosis and treatment of acute ST segment elevation myocardial infarction (2019), patients with acute anterior ST segment elevation myocardial infarction were diagnosed;
•3. Patients with primary acute myocardial infarction;
•4. Patients who completed PCI reperfusion treatment within 12 hours after the onset of the disease;
•5. Patients with Killip grading between I and III;
•6. Subjects participated in the study voluntarily and signed informed consent.

•1. Patients with previous cardiac insufficiency caused by other diseases (valvular heart disease, congenital heart disease, pericardial disease, arrhythmia, other non cardiac causes);
•2. The patients underwent CABG within 12 weeks;
•3. Patients undergoing cardiac resynchronization;
•4. Patients with left ventricular outflow tract obstruction;
•5. Patients with myocarditis;
•6. Patients with uncontrolled severe arrhythmia;
•7. Patients with aortic aneurysm;
•8. Patients with serious liver, kidney, blood system, mental disease or systemic disease;
•9. Significant liver and kidney dysfunction (ALT > 2.0 times the upper limit of normal value; creatinine > 1.5 times the upper limit of normal value);
•10. Patients with serum potassium > 5.5mmol/l;
•11. Uncontrolled hypertension (higher than 180 / 110mmhg);
•12. Pregnant or lactating women;
•13. Patients allergic to compound Danshen Dropping Pills;
•14. Patients participating in clinical studies of other drugs.

发起方

The First Affiliated Hospital of Nanjing Medical University